Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Authors

Showing 4 results for author "Rukash Khan Niazi".

Back to authors

Thumbnail for Cardiac Safety of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Real-World Propensity-Matched Comparison of Dasatinib, Nilotinib, and Imatinib

CML - 1166

Cardiac Safety of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Real-World Propensity-Matched Comparison of Dasatinib, Nilotinib, and Imatinib

Rukash Khan Niazi

Poster Presenter: Rukash Khan Niazi

Thumbnail for Cardiovascular and Survival Outcomes Among Adults With Hematologic Malignancies Receiving Anthracyclines With vs Without Dexrazoxane: A Real-World Propensity-Matched Analysis

CT - 1348

Cardiovascular and Survival Outcomes Among Adults With Hematologic Malignancies Receiving Anthracyclines With vs Without Dexrazoxane: A Real-World Propensity-Matched Analysis

Rukash Khan Niazi

Poster Presenter: Rukash Khan Niazi

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

$Thumbnail for Comparative Real-World Outcomes of CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Propensity-Matched TriNetX Analysis$

MM - 1370

Comparative Real-World Outcomes of CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Propensity-Matched TriNetX Analysis

Rukash Khan Niazi

Poster Presenter: Rukash Khan Niazi

Thumbnail for Comparative Effectiveness and Safety of Talquetamab Versus Teclistamab in Multiple Myeloma: A Real-World Propensity-Matched Study

MM - 1377

Comparative Effectiveness and Safety of Talquetamab Versus Teclistamab in Multiple Myeloma: A Real-World Propensity-Matched Study

Rukash Khan Niazi

Poster Presenter: Rukash Khan Niazi

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors